JP2016516721A5 - - Google Patents

Download PDF

Info

Publication number
JP2016516721A5
JP2016516721A5 JP2016502966A JP2016502966A JP2016516721A5 JP 2016516721 A5 JP2016516721 A5 JP 2016516721A5 JP 2016502966 A JP2016502966 A JP 2016502966A JP 2016502966 A JP2016502966 A JP 2016502966A JP 2016516721 A5 JP2016516721 A5 JP 2016516721A5
Authority
JP
Japan
Prior art keywords
difficile
toxoid
toxin
formaldehyde
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016502966A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016516721A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/029035 external-priority patent/WO2014144567A2/en
Publication of JP2016516721A publication Critical patent/JP2016516721A/ja
Publication of JP2016516721A5 publication Critical patent/JP2016516721A5/ja
Pending legal-status Critical Current

Links

JP2016502966A 2013-03-15 2014-03-14 トキソイド、組成物および関連方法 Pending JP2016516721A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361790423P 2013-03-15 2013-03-15
US61/790,423 2013-03-15
PCT/US2014/029035 WO2014144567A2 (en) 2013-03-15 2014-03-14 Toxoid, compositions and related methods

Publications (2)

Publication Number Publication Date
JP2016516721A JP2016516721A (ja) 2016-06-09
JP2016516721A5 true JP2016516721A5 (cg-RX-API-DMAC7.html) 2017-05-18

Family

ID=50489430

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016502966A Pending JP2016516721A (ja) 2013-03-15 2014-03-14 トキソイド、組成物および関連方法

Country Status (13)

Country Link
US (2) US20160045586A1 (cg-RX-API-DMAC7.html)
EP (1) EP2968507A2 (cg-RX-API-DMAC7.html)
JP (1) JP2016516721A (cg-RX-API-DMAC7.html)
KR (1) KR20150133770A (cg-RX-API-DMAC7.html)
CN (1) CN105338997A (cg-RX-API-DMAC7.html)
AR (1) AR095669A1 (cg-RX-API-DMAC7.html)
AU (1) AU2014228956A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015023332A2 (cg-RX-API-DMAC7.html)
CA (1) CA2907154A1 (cg-RX-API-DMAC7.html)
HK (1) HK1213800A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201507608PA (cg-RX-API-DMAC7.html)
TW (1) TWI624474B (cg-RX-API-DMAC7.html)
WO (1) WO2014144567A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086199A1 (es) 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
SG11201510166YA (en) 2013-06-14 2016-01-28 Sanofi Pasteur Inc Compositions and methods of immunizing against c. difficile
BR112017024443A2 (pt) * 2015-05-15 2018-10-23 Sanofi Pasteur Inc métodos para imunização contra clostridium difficile
MX388528B (es) 2017-06-09 2025-03-20 Hipra Scient S L U Vacuna que comprende toxoides de clostridium.
US10096313B1 (en) * 2017-09-20 2018-10-09 Bose Corporation Parallel active noise reduction (ANR) and hear-through signal flow paths in acoustic devices
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
EP4444742A4 (en) * 2021-12-06 2025-12-10 Univ Rutgers Compositions and Methods for Treating Cancer
EP4658302A1 (en) 2023-02-02 2025-12-10 GlaxoSmithKline Biologicals S.A. Immunogenic composition

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
US5610023A (en) * 1995-03-31 1997-03-11 Lee Laboratories, Inc. Method of purification of clostridium difficile toxin A and production of mono-specific antibodies
US6969520B2 (en) * 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
EP2305303A3 (en) * 1997-10-20 2013-11-13 Sanofi Pasteur Biologics Co. Immunization against Clostridium difficile disease
US6669520B2 (en) 2001-09-19 2003-12-30 United Microelectronics Corp. Method of fabricating an LC panel
JP2010534622A (ja) 2007-07-26 2010-11-11 サノフィ パストゥール リミテッド 抗原−アジュバント組成物および方法
AU2008299885C1 (en) * 2007-09-14 2015-06-25 Sanofi Pasteur Biologics, Llc Pharmaceutical compositions containing clostridium difficile toxoids A and B
GB201011968D0 (en) * 2010-07-16 2010-09-01 Secr Defence Toxoiding method

Similar Documents

Publication Publication Date Title
WO2021155243A8 (en) Respiratory virus immunizing compositions
EP4588521A3 (en) Polypeptide-antigen conjugates with non-natural amino acids
PH12017501445A1 (en) Methods for producing virus for vaccine production
NZ622731A (en) Increasing virus-like particle yield in plants
PH12015500633A1 (en) Method for preparing imp fermented broth or glutamic acid fermented broth as raw material for preparation of natural flavor
CN106659777A8 (zh) 免疫原性组合产品
NZ616304A (en) Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
MY165831A (en) Methods of reducing virucidal activity in pcv-2 compositions and pcv-2 compositions with a improved immunogenicity
MX390947B (es) Composiciones terapéuticas de ceramidasa ácida y métodos para prepararlas y utilizarlas.
JP2015134763A5 (cg-RX-API-DMAC7.html)
UA110024C2 (uk) Вакцинний вектор і спосіб посилення імунної відповіді
PH12015501333A1 (en) Method of making a mycoplasma vaccine
PH12015500628A1 (en) Method for preparing natural kokumi flavor
RU2010134400A (ru) Способ получения "теней"бактериальных клеток (bg)
MY183566A (en) Rotavirus-like particle production in plants
EA201890407A1 (ru) Бактерии lactobacillus fermentum, уменьшающие концентрацию ацетальдегида
PH12020550976A1 (en) Camp receptor protein variant and method of producing l-amino acid using the same
GEP20247684B (en) Combination vaccine composition comprising reduced dose inactivated poliovirus and method for preparing the same
MX385961B (es) Un método para la activación de bacterias de ácido láctico.
ZA202401405B (en) Compositions and methods for anti-pacap antibodies
RU2017141773A (ru) Микроорганизм рода Escherichia, продуцирующий L-триптофан, и способ получения L-триптофана с его использованием
GB1430711A (en) Live bovine and method ofvaccination using them
MX2021011913A (es) Composiciones de virus inactivado y formulaciones de vacunas contra el zika.
JP2017509713A5 (cg-RX-API-DMAC7.html)
GEP20257808B (en) Immunogenic compositions against enteric diseases and methods for its preparation thereof